Literature DB >> 15877004

Transcutaneous oxygen pressure measurements (tcpO2) at ankle during exercise in arterial claudication.

P Abraham1, J Picquet, P Bouyé, P L'Hoste, B Enon, B Vielle, J L Saumet.   

Abstract

AIM: Although a time consuming technique, tcpO2 provides complementary information as compared to other tests. Simultaneous recording of systemic and peripheral oxygen pressure changes with exercise could be interesting to confirm that local hypoxemia is of arterial origin, but accuracy versus gold standard arteriography and objectively determined cut-off points to be used in arterial claudication at the ankle are not reported. EXPERIMENTAL
DESIGN: retrospective plus prospective study.
SETTING: institutional practice, ambulatory care. PATIENTS: 100 patients suffering stage 2 claudication (group A) were retrospectively studied to objectively define cut-off points derived from tcpO2 recordings to be used in exercise testing. Then, applicability and reproducibility of these cut-off points were analysed prospectively in another 50 patients (group B). INTERVENTION: tcpO2 was measured on both calves and with a chest reference electrode. Arteriography on each side was quoted positive for a diameter stenosis superior to 75% or occlusion on the aorto-popliteal axis or of all-3-calf arteries.
RESULTS: The best performance was obtained with tcpO2 changes from rest at the calf normalised to eventual chest changes (DROP) during or following the treadmill test. Optimal cut-off point determined through ROC curve analysis for DROP was -15 mmHg in group A. Applying this cut-off point in group B provided a 86/84% sensitivity/specificity and showed excellent reproducibility.
CONCLUSIONS: TcpO2 measurement on the calf during exercise could be useful in a selected population of patients with claudication of questionable vascular origin and/or when other non-invasive investigations cannot be performed.

Entities:  

Mesh:

Year:  2005        PMID: 15877004

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  6 in total

1.  A Simple Scale for Screening Lower-Extremity Arterial Disease as a Possible Cause of Low Back Pain: a Cross-sectional Study Among 542 Subjects.

Authors:  M Gahier; J Hersant; J F Hamel; Y Sempore; A Bruneau; S Henni; P Abraham
Journal:  J Gen Intern Med       Date:  2020-05-04       Impact factor: 5.128

2.  Comparison of exercise oximetry and ankle pressure measurements for patients with intermittent claudication: an observational study of 433 patients.

Authors:  Pierre Abraham; Jeanne Hersant; Pierre Ramondou; Jean Picquet; Mathieu Feuilloy; Samir Henni
Journal:  Pflugers Arch       Date:  2020-01-03       Impact factor: 3.657

3.  Exercise transcutaneous oxygen pressure measurement has good sensitivity and specificity to detect lower extremity arterial stenosis assessed by computed tomography angiography.

Authors:  Caroline Koch; Emmanuel Chauve; Ségolène Chaudru; Alexis Le Faucheur; Vincent Jaquinandi; Guillaume Mahé
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

4.  Microvascular Response to the Roos Test Has Excellent Feasibility and Good Reliability in Patients With Suspected Thoracic Outlet Syndrome.

Authors:  Samir Henni; Jeanne Hersant; Myriam Ammi; Fatima-Ezzahra Mortaki; Jean Picquet; Mathieu Feuilloy; Pierre Abraham
Journal:  Front Physiol       Date:  2019-02-21       Impact factor: 4.566

5.  Combination of Exercise Testing Criteria to Diagnose Lower Extremity Peripheral Artery Disease.

Authors:  Olivier Stivalet; Anita Paisant; Dihia Belabbas; Alexis Le Faucheur; Philippe Landreau; Estelle Le Pabic; Loukman Omarjee; Guillaume Mahé
Journal:  Front Cardiovasc Med       Date:  2021-11-17

6.  Stimulation TcPO2 Testing Improves Diagnosis of Peripheral Arterial Disease in Patients With Diabetic Foot.

Authors:  Vladimíra Fejfarová; Jiří Matuška; Edward Jude; Pavlína Piťhová; Milan Flekač; Karel Roztočil; Veronika Wosková; Michal Dubský; Alexandra Jirkovská; Robert Bém; Jitka Husáková; Věra Lánská
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-10       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.